The cardiovascular drug Clonidine Tablet was approved for marketing in Australia and Canada in November 2016 and March 2017, respectively.

 Since the successful launch of Yung-Shin's Clonidine Tablet in the United States in 2013, Yung-Shin, adhering to its corporate philosophy of "providing the best quality medicines to improve human health," has registered its high-quality Clonidine in Canada, as well as in Australia and New Zealand in the Southern Hemisphere. It was approved for marketing in Australia in November 2016 and Canada in March 2017, demonstrating our unwavering commitment to leveraging our expertise to establish a foothold in Taiwan while expanding globally.

Clonidine Tablet is currently the most widely used antihypertensive medication. It primarily works by suppressing the brain's vasoconstriction control center, indirectly causing vasodilation and improving blood flow, thereby lowering blood pressure. This medication is typically used to treat mild to moderate hypertension, either alone or in combination with other antihypertensive medications. It can also be used to prevent migraines.